Moderna (NASDAQ:MRNA) Sets New 12-Month High - Here's Why

Moderna rallies 12% to set new high (MRNA:NASDAQ)

Moderna (MRNA) hits a new 52-week high on ESMO 2026 oncology data plans as intismeran buzz grows.

Moderna (NASDAQ:MRNA) Sets New 12-Month High - Here's Why

Moderna (NASDAQ:MRNA) Sets New 1-Year High - Here's Why

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.

Moderna Stock’s 13% Rally Sets a $70 Billion Test for October Cancer Data

New York, September 21, 2026, 15:54 (EDT) Moderna rose 13.00% to $174.06 and touched a 52-week high.Full Phase 3 melanoma data are scheduled for October 24.The stock trades 71% above Wall Street's average price target. Moderna, Inc. (NASDAQ:MRNA) climbed 13.00% to $174.06 on Monday afternoon, touching a 52-week high of $176.86. A newly dated cancer-vaccine…